StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The expected earnings improvement and revenue growth signal a positive trend for CRMD.
What happened, with direct paths to the underlying reporting
CorMedix will report Q4 earnings on March 25. Analysts forecast earnings at 14 cents per share. CorMedix projects revenue of $28.34 million. Recent promotions for DefenCath® target VA facilities. Analysts have raised CRMD price targets recently.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.